Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation

Woywodt, A.; Haubitz, M.; Buchholz, S.; Hertenstein, B.
December 2004
Bone Marrow Transplantation;Dec2004, Vol. 34 Issue 12, p1015
Academic Journal
Summary:During hematopoietic stem cell transplantation (HSCT), endothelial damage is the pathological hallmark of veno-occlusive disease of the liver, thrombotic microangiopathy, capillary leak syndrome and graft-versus-host disease. Events prior to conditioning, the conditioning regimen itself as well as calcineurin inhibitors may all induce endothelial damage. Unfortunately, the relative importance of these factors and their interactions, the time frame of endothelial damage and individual susceptibility remain unknown. Moreover, it is conceivable that conditioning regimens differ markedly in their propensity to initiate endothelial damage. Monitoring endothelial damage and response to treatment is hampered by the current lack of suitable markers. In this regard, an ideal marker should be sensitive and specific and indicate the development of an endothelial disorder prior to the onset of symptoms and organ dysfunction. Soluble markers, such as thrombomodulin, are easily amenable with immunoassays; yet, the interpretation of their levels is hampered by the influence of comorbidity. Evaluation of circulating endothelial cells in HSCT demonstrated a marked and dose-dependent increase in cell numbers after conditioning. The challenge ahead is to establish and evaluate novel markers of endothelial damage to permit early detection of disease, monitor response to treatment and evaluate different conditioning regimens.Bone Marrow Transplantation (2004) 34, 1015-1023. doi:10.1038/sj.bmt.1704733 Published online 1 November 2004


Related Articles

  • Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. George, J. N. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p917 

    The author reflects on the importance of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA). He remarks that TA-TMA's importance is documented not only by the experience of clinicians but also by extensive clinical investigation. He asserts that despite...

  • Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Cho, B.-S.; Min, C.-K.; Eom, K.-S.; Kim, Y.-J.; Kim, H.-J.; Lee, S.; Cho, S.-G.; Kim, Y.; Kim, D.-W.; Lee, J.-W.; Min, W.-S.; Kim, C.-C. // Bone Marrow Transplantation;May2008, Vol. 41 Issue 9, p813 

    The impact of thrombotic microangiopathy (TMA) on outcome was studied in 148 patients with acute graft-versus-host disease (GVHD) (grade II). The Blood and Marrow Transplant Clinical Trials Network's definition for TMA was used to diagnose definite TMA. Probable TMA was diagnosed when...

  • Enhancing bone marrow regeneration by SALL4 protein. Wenbin Liao; Aguila, Jerell R.; Yixin Yao; Jianchang Yang; Gary Zieve; Yongping Jiang; Avila, Cecilia; Lisa Senzel; Lai, Raymond; Dazhong Xu; Wei Dai; Yupo Ma // Journal of Hematology & Oncology;2013, Vol. 6 Issue 1, p1 

    Hematopoietic stem cells (HSCs) are widely used in transplantation therapy to treat a variety of blood diseases. The success of hematopoietic recovery is of high importance and closely related to the patient's morbidity and mortality after Hematopoietic stem cell transplantation (HSCT). We have...

  • Mothers' Perceptions of Benefit Following Pediatric Stem Cell Transplantation: A Longitudinal Investigation of the Roles of Optimism, Medical Risk, and Sociodemographic Resources. Rini, Christine; Manne, Sharon; Duhamel, Katherine N.; Austin, Jane; Ostroff, Jamie; Boulad, Farid; Parsons, Susan K.; Martini, Richard; Williams, Sharon E.; Mee, Laura; Sexson, Sandra; Redd, William H. // Annals of Behavioral Medicine;2004, Vol. 28 Issue 2, p132 

    Background: This longitudinal study investigated the course and predictors of benefit finding among 144 mothers of children undergoing hematopoietic stem cell transplantation (HSCT), a severely stressful and life-threatening medical procedure. Purpose: Children's medical risk and mothers'...

  • Hematopoietic stem cell transplantation for autoimmune diseases in developing countries: current status and future prospectives. Voltarelli, J C; Ouyang, J // Bone Marrow Transplantation;Aug2003 Supplement 1, Vol. 32 Issue 1, pS69 

    Summary:In this paper we present preliminary results of hematopoietic stem cell transplantation for autoimmune diseases in Brazil and China. Chinese experience transplanting lupus is significant and the Brazilian experience with several autoimmune diseases is growing. We discuss peculiar...

  • Hematopoietic stem cell transplantation for severe rheumatoid arthritis. Moore, J J; Snowden, J; Pavletic, S; Barr, W; Burt, R // Bone Marrow Transplantation;Aug2003 Supplement 1, Vol. 32 Issue 1, pS53 

    Summary:The substantial morbidity and mortality associated with rheumatoid arthritis (RA), while not widely appreciated, provide adequate justification for consideration of high-dose immunoablative therapy followed by hematopoietic stem cell transplantation. While some patients with RA follow a...

  • Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus. Burt, R K; Marmont, A; Arnold, R; Heipe, F; Firestein, G S; Carrier, E; Hahn, B; Barr, W; Oyama, Y; Snowden, J; Kalunian, K; Traynor, A // Bone Marrow Transplantation;Aug2003 Supplement 1, Vol. 32 Issue 1, pS49 

    Summary:At Northwestern University, a phase I/II trial of hematopoietic stem cell transplant (HSCT) for systemic lupus erythematosus (SLE) has shown promising results. A phase III HSCT trial is being developed to confirm efficacy of HSCT vs continuing the currently accepted standard of care,...

  • Hematopoietic stem cell transplantation for multiple sclerosis: finding equipoise. Burt, R K; Kozak, T // Bone Marrow Transplantation;Aug2003 Supplement 1, Vol. 32 Issue 1, pS45 

    Summary:Hematopoietic stem cell transplantation of multiple sclerosis is rapidly expanding. Success for this approach requires an understanding of the pathophysiology of multiple sclerosis and design of trials that select patients with active inflammatory disease, low disability scores, and...

  • Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Khan, F.; Agarwal, A.; Agrawa, S. // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 1, p1 

    Summary:The main goal of post-transplantation monitoring in hematopoietic stem cell transplantation (HSCT) is to predict negative events, such as disease relapse, graft rejection and graft-versus-host disease, in order to intervene with appropriate therapy. In this context, chimerism analysis is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics